Juva Life Launches Journal App, Offering Personal Health

VANCOUVER, British Columbia, March 02, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing in cannabis production operations and distribution , announced today the launch of the Company’s Journal App, designed to help cannabis users and patients track their consumption, and gain insight into how cannabis products affect their health and wellness.

“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” said Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”

Through the Journal App, cannabis consumers and anyone who uses hemp-based cannabidiol (CBD) products can track their symptoms, medication use and results. Consumers can track a variety of health ailments, while documenting the products they consumed, the effect they had on their specific symptoms and any side effects that may occur.

“In all industries, data is king. Through both the Journal App and our WIRB-approved registry, we are curating one of the largest repositories of real-world data on the medical effects of cannabis use, including consumption behavior and perceived effectiveness. While we remain committed to the privacy of our users, the data we are collecting will be beneficial from a regulatory and scientific standpoint and adds significant value to Juva’s intellectual property portfolio,” added Chloupek. “All user info associated with the Journal App and the WIRB-approved registry is protected by the strictest patient privacy laws in the world, so participants can rest assured their entries are 100% confidential; any data imputed is anonymized for patient privacy.”

Those interested in downloading the Journal App can do so here: https://shopjuva.com/journalapp/

The Company is also running a WIRB-approved multi-year study through its cannabis research registry. Once Juva will have one of completed the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.

Juva Life also has a pharmaceutical research and life sciences division, with a goal of identifying the mode of action behind cannabis’ anecdotal ability to regulate inflammation. The Company recently identified non-cannabinoid compounds JUVA-019 and JUVA-041, on which the Company has filed patent applications and has conducted preclinical research showing the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body . JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further preclinical investigation, are currently advancing through phenotypic models of chronic diseases of aging.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing a state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend” , “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing at reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties” . Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors , may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligations to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

.

Leave a Comment